Autopsy report · NCT04393675

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients

“Change in the clinical development plan”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 3 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Lumosa Therapeutics Co., Ltd.

Sponsor type

Industry

Conditions

Uremic Pruritus

Interventions

LT5001; Placebo

Participants

18

Sites

1

Countries

Taiwan

Trials that died the same way

• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
  “the change of clinical development plan” (99% match in meaning)
• Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee
  “Amended clinical development plan.” (88% match in meaning)
• Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS
  “Change in development plan” (77% match in meaning)
• A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
  “Development plan change” (76% match in meaning)
• A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo
  “Change in clinical strategy” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.